Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2189)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Dec 24, 2023 (publication date) through Jun 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang N, Chen FL, Pan L, Teng Y, Wei XJ, Guo HG, Jiang XM, Huang L, Liu SC, Liang ZL, Li WY. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy. World J Clin Oncol 2023; 14(12): 606-619 [PMID: 38179402 DOI: 10.5306/wjco.v14.i12.606] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v14/i12/606.htm |
| Number | Citing Articles |
| 1 |
Leonardo S Lino-Silva, Sabrina B Martínez-Villavicencio, Luisa Fernanda Rivera-Moncada. Bruton’s tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon. World Journal of Clinical Oncology 2024; 15(5): 587-590 doi: 10.5306/wjco.v15.i5.587
|
| 2 |
Budhi Singh Yadav. High-dose methotrexate and zanubrutinib combination therapy for primary central nervous system lymphoma. World Journal of Clinical Oncology 2024; 15(3): 371-374 doi: 10.5306/wjco.v15.i3.371
|